Loading data for APRE — first visit, this takes a few seconds.
Aprea Therapeutics, Inc. (APRE)
NasdaqCM: APRE
· 即時價格 · USD
0.79
-0.02 (-2.47%)
收盤價： Sep 09, 2026, 8:00 PM
股價、關鍵數字和最新消息，都在這一頁。
Aprea Therapeutics, Inc.（APRE）股價、分析與資料
無可用資料
| 買價 | 0.8 |
| 市值 | 9.96M |
| 營收 (ttm) | 5.18K |
| 淨利（ttm） | -12.3M |
| 1.63 | |
| -0.9 | |
| n/a | |
| -2.33 | |
| P/B (ttm) | 0.25 |
| P/S (ttm) | 1921.82 |
| 財報日期 | n/a |
| 賣價 | 0.86 |
| 成交量 | 89,398 |
| 20 日平均成交量 | 229,887 |
| 開盤價 | 0.80 |
| 前收盤價 | 0.81 |
| 當日區間 | 0.79 - 0.81 |
| 52 週範圍 | 0.55 - 1.69 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor,...
完整的公司簡介財報驚奇
Aprea Therapeutics 已於 Aug 12, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.07 超出預期 0.16, 年增 86.79% 成長.
第 1 頁，共 2 頁